152 related articles for article (PubMed ID: 35254758)
1. Analysis of Reddit Reveals Dupilumab Questions Among Atopic Dermatitis Patients.
Kurtti A; Cohen M; Jagdeo J
J Drugs Dermatol; 2022 Mar; 21(3):292-294. PubMed ID: 35254758
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Reddit Reveals Atopic Dermatitis Patient Questions.
Kurtti A; Jagdeo J
J Drugs Dermatol; 2021 Jun; 20(6):653-658. PubMed ID: 34076394
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients.
Ahuja K; DeSena G; Lio P
J Drugs Dermatol; 2024 Apr; 23(4):e121-e123. PubMed ID: 38564385
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
5. Skin of Color Sun Protection: Reddit Analysis Reveals Perceptions, Preferences, Unmet Needs, and Knowledge Gaps.
Mineroff J; Kurtti A; Jagdeo J
J Drugs Dermatol; 2023 Jul; 22(7):673-677. PubMed ID: 37410046
[TBL] [Abstract][Full Text] [Related]
6. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab Improves Atopic Dermatitis and Post-Inflammatory Hyperpigmentation in Patient With Skin of Color.
Grayson C; Heath CR
J Drugs Dermatol; 2020 Jul; 19(7):776-778. PubMed ID: 32726553
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab for the Treatment of Atopic Dermatitis.
Ferreira S; Torres T
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
13. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
[TBL] [Abstract][Full Text] [Related]
14. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
15. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis.
Yamane MLM; Belsito DV; Glass LRD
Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518
[TBL] [Abstract][Full Text] [Related]
16. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
Blakely K; Gooderham M; Papp K
Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
19. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
20. Angioedema: A potential complication of dupilumab in atopic dermatitis.
Fritz AL; Lacy FA; Morrell DS
Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
